CASI Pharmaceuticals, Inc. (CASI)
| Market Cap | 420.17M |
| Revenue (ttm) | 11.66M |
| Net Income (ttm) | -46.99M |
| Shares Out | 117.94M |
| EPS (ttm) | -0.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $3.39 |
| Previous Close | $3.25 |
| Change ($) | 0.14 |
| Change (%) | 4.31% |
| Day's Open | 3.18 |
| Day's Range | 3.16 - 3.39 |
| Day's Volume | 221,501 |
| 52-Week Range | 1.44 - 3.46 |
ROCKVILLE, Md. and BEIJING, Jan. 21, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative thera...
ROCKVILLE, Md., and BEIJING, Jan. 8, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative thera...
ROCKVILLE, Md., and BEIJING, Dec. 23, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative ther...
ROCKVILLE, Md. and BEIJING, Nov. 18, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative thera...
CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2020 Results - Earnings Call Transcript
Shares of CASI Pharmaceuticals (NASDAQ:CASI) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share fell 40.00% over the past year to ($0.14), which mi...
ROCKVILLE, MD., and BEIJING, Nov. 5, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative thera...
CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkp...
CASI's pipeline expanded to include first-in-class monoclonal antibody developed to unlock anti-cancer immunity in liquid and solid tumors Collaboration accelerates and expands BioInvent's glo...
ROCKVILLE, Md. and BEIJING, Oct. 2, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therap...
ROCKVILLE, Md. and BEIJING, Sept.
Shares of CASI Pharmaceuticals (NASDAQ:CASI) moved higher by 1.6% in pre-market trading after the company reported Q2 results.
ROCKVILLE, Md. and BEIJING, Aug.
ROCKVILLE, Md. and BEIJING, Aug.
These strong stocks to buy benefited from atypical and big insider buying activity over the past few weeks. The post 5 Stocks to Buy Because of Heavy Insider Buying in July appeared first on ...
ROCKVILLE, Md. and BEIJING, July 22, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc.
ROCKVILLE, Md. and BEIJING, July 21, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc.
ROCKVILLE, Md. and BEIJING, June 8, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therap...
ROCKVILLE, Md., and BEIJING, June 2, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative thera...
CASI Pharmaceuticals: 2-Year Price Lows Make For Intriguing Risk-On Buy
CEO of Casi Pharmaceuticals Inc (30-Year Financial, Insider Trades) Wei-wu He (insider trades) bought 20,000 shares of CASI on 08/16/2019 at an average price of $3.2 a share.
CEO of Casi Pharmaceuticals Inc (30-Year Financial, Insider Trades) Wei-wu He (insider trades) bought 160,000 shares of CASI on 08/14/2019 at an average price of $3.17 a share.
About CASI
CASI Pharmaceuticals, a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute... [Read more...]
| Industry Biotechnology | IPO Date Jun 11, 1996 |
| CEO Wei-Wu He | Employees 125 |
| Stock Exchange NASDAQ | Ticker Symbol CASI |
Analyst Forecasts
According to 2 analysts, the average rating for CASI stock is "Buy." The 12-month stock price forecast is 4.00, which is an increase of 17.99% from the latest price.